InMed Pharmaceuticals Inc.
INM
$1.51
-$0.02-1.31%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -26.77% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -26.77% | |||
| Cost of Revenue | -- | -11.30% | |||
| Gross Profit | -- | -54.32% | |||
| SG&A Expenses | 7.46% | 5.82% | |||
| Depreciation & Amortization | -2.82% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.23% | 1.98% | |||
| Operating Income | -32.81% | -20.24% | |||
| Income Before Tax | -37.65% | -17.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -37.65% | -17.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -46.25% | -17.45% | |||
| EBIT | -32.81% | -20.24% | |||
| EBITDA | -33.78% | -20.87% | |||
| EPS Basic | -42.87% | -17.45% | |||
| Normalized Basic EPS | -34.44% | -17.48% | |||
| EPS Diluted | -42.87% | -17.45% | |||
| Normalized Diluted EPS | -34.44% | -17.48% | |||
| Average Basic Shares Outstanding | 2.37% | 0.00% | |||
| Average Diluted Shares Outstanding | 2.37% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||